SignalXSignalX

ENOV Enovis CORP

Q4 2025 10-Q
Filed: Nov 6, 2025Period ending Oct 3, 2025
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR
Enovis CORP Overview

Enovis CORP (ENOV) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Oct 3, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q4 2025 10-Q

Risk Factors

  • • New Goodwill impairment risk triggered by 40% stock price decline, recognized $541M impairment Q3 2025 due to sustained market capitalization decrease
  • • Updated impairment risk: total $1.186B Goodwill impairments recognized including $645M in 2024 annual test and $541M in 2025 interim assessment
+3 more insights

Get deeper insights on Enovis CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.